Enliven Therapeutics, Inc.

NasdaqGS ELVN

Enliven Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -11.73

Enliven Therapeutics, Inc. Price to Earnings Ratio (P/E) is -11.73 on January 14, 2025, a -61.88% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Enliven Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -6.84 on January 17, 2024, which is 41.65% above the current Price to Earnings Ratio (P/E).
Enliven Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -16.94 on November 06, 2024, which is -44.43% below the current Price to Earnings Ratio (P/E).
Enliven Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -12.92.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: ELVN

Enliven Therapeutics, Inc.

CEO	Mr. Samuel S. Kintz M.B.A.
IPO Date	March 12, 2020
Location	United States
Headquarters	6200 Lookout Road
Employees	46
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Key trends

Past 5 years